Only discontinue if you experience severe allergic reactions, spreading infection, or if your healthcare provider recommends stopping
They can provide guidance on whether adjustments may be appropriate
Why Researchers Choose Semaglutide Over Dual or Triple Agonists Versus Tirzepatide (GLP-1/GIP Dual): Tirzepatide adds a second pathway (GIP) that improves insulin sensitivity and may moderate gastrointestinal side effects, producing greater total weight loss (~20-22% vs ~15-17%)
Gastrointestinal effects during transitions Nausea is the most common side effect of both medications, affecting roughly 44% of semaglutide users and a similar percentage of tirzepatide users in clinical trials
Spreading protein intake throughout the day, rather than concentrating it in one meal, optimizes muscle protein synthesis
For a glossary of every term in this table, the peptide research glossary defines GHS-R1a, somatostatin, GHRH, pulsatility and the rest